HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF

HUTCHMED (China) Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026

$14.18+0.13 (+0.93%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 27.3
Dividend yield: –

HUTCHMED (China) Ltd income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	549	630	838	426	356	228	205	214	241	216	178	87
Cost of Revenue	336	349	384	311	–	–	–	–	170	149	105	53
Gross Profit	212	281	454	115	–	–	–	–	71	67	73	34
Research & Development	148	212	302	387	299	175	138	114	76	67	47	30
General & Administrative	67	64	80	92	89	50	39	31	24	22	20	13
Operating Expenses	–	–	–	–	–	–	–	–	–	263	188	106
Total Costs & Expenses	588	674	820	834	684	425	351	307	295	263	188	–
Operating Income	-39	-44	18	-408	-328	-197	-146	-93	-53	-47	-9.77	-18
Interest Expense	2.87	2.87	0.76	0.65	0.59	0.79	1.03	1.01	1.46	1.63	1.40	1.52
Interest & Investment Income	50	40	36	9.60	2.08	3.24	4.94	5.98	1.22	0.50	0.45	0.56
Income from Equity Investments	23	46	47	50	61	79	41	19	34	66	23	15
Other Non-Operating Income	61	43	40	-2.73	-8.73	6.93	5.28	5.99	-0.12	-0.66	-0.77	-1.70
Asset Impairment Charges	0.09	2.92	3.68	–	–	–	–	–	0	0	0	0
Gain (Loss) on Sale of Assets	0.02	-0.01	-0.09	-0.11	-0.07	-0.09	-0.02	-0.03	-0.06	-0.03	-0.06	-0.04
Pretax Income	499	-1.11	58	-410	-216	-190	-141	-87	-54	-47	-11	-3.26
Income Tax Expense	64	7.19	4.51	-0.28	12	4.83	3.27	3.96	3.08	4.33	1.61	1.34
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	12	-35	-34
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	2.03
Net Income incl. Noncontrolling Interests	458	38	101	-360	-167	-116	-104	-71	-23	15	10	-4.09
Minority Interest in Earnings	0.82	0.44	0.31	0.45	28	10	2.35	3.52	3.77	2.86	2.43	3.22
Net Income	457	38	101	-361	-195	-126	-106	-75	-27	12	7.99	-7.31
Net Income to Common	–	–	–	–	–	–	–	–	-27	12	-35	-33
EPS (Basic)(per share)	0.53	0.04	0.12	-0.43	-0.25	-0.18	-0.16	-0.11	-0.04	0.02	-0.06	-0.06
EPS (Diluted)(per share)	0.52	0.04	0.12	-0.43	-0.25	-0.18	-0.16	-0.11	-0.04	0.02	-0.06	-0.06
Shares Outstanding (Basic, Weighted)(shares)	858	855	850	847	793	698	666	664	617	597	547	526
Shares Outstanding (Diluted, Weighted)(shares)	873	873	869	847	793	698	666	664	617	600	547	526
EBITDA	-26	-31	27	-399	-321	-191	-141	-89	-51	-44	-7.76	-17

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 38.7%
Operating margin: -7.1%
Net margin: 83.3%
Return on equity, FY2025: 45.7%

Financial strength

Current ratio: 5.64
Debt to equity: 0.09
Debt to assets: 6.7%
Cash to current liabilities: 38.7%

Valuation

P/E ratio: 27.3
Price to sales: –
Price to book: –
Dividend yield: –